Is Avian influenza virus still threatening humans? Preventative measures and treatment
DOI:
https://doi.org/10.12775/QS.2025.37.57463Keywords
Zoonotic influenza, pandemic influenza, preparedness, vaccineAbstract
Introduction
Global shift in the ecology of highly pathogenic avian influenza strains like H5N1 and the spread of avian influenza to mammals are raising concerns and prompting action in the event of a pandemic. Due to the nature of viruses, a future influenza pandemic is inevitable and preparedness for it vital. The aim of this article is to present the developed strategies for preventing pandemic influenza as a measure of preparedness for the upcoming threat.
State of knowledge
For public health purposes, influenza is divided into: seasonal, zoonotic and pandemic [1]. Although pandemic influenza spread very rare, it is of great concern due to its global reach and high mortality rate [2]. Health experts are concerned that a future pandemic could be caused by the H5N1 strain of the virus, an infection that can spread from birds to humans [3]. WHO, in collaboration with other institutions, continuously monitors influenza viruses. Based on risk assessment, it issues guidelines, develops surveillance strategies, and establishes a pandemic response plan. As part of preparedness for the next pandemic, specific influenza vaccines are developed and available antiviral drugs are being tested for their effectiveness against strains with pandemic potential.
Summary
Having appropriate policy and planning in place facilitates early response in order to suppress an influenza outbreak quickly, thus reducing the potentially catastrophic future impacts of a pandemic. Currently available antiviral medicines are mostly effective against the highly pathogenic strains of influenza A virus of concern. The Zoonotic influenza vaccines contains a strain matching the currently circulating clade to ensure protection. Effective plans will not succeed without the will to implement and execute them.
References
1. World Health Organization (WHO), Teams, Global Influenza Programme, Pandemic influenza preparedness https://www.who.int/teams/global-influenza-programme/public-health-preparedness (access: 2024.06.07)
2. Monto AS, Fukuda K. Lessons From Influenza Pandemics of the Last 100 Years. Clinical Infectious Diseases 2019:ciz803. https://doi.org/10.1093/cid/ciz803
3. Yamaji R, Saad MD, Davis CT, Swayne DE, Wang D, Wong FYK, et al. Pandemic potential of highly pathogenic avian influenza clade 2.3.4.4 A(H5) viruses. Reviews in Medical Virology 2020;30:e2099. https://doi.org/10.1002/rmv.2099
4. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD). Understanding Flu Viruses, Types of Influenza Viruses. https://www.cdc.gov/flu/about/viruses/types.htm (access: 2024.06.07)
5. Sutton TC. The Pandemic Threat of Emerging H5 and H7 Avian Influenza Viruses. Viruses 2018;10:461. https://doi.org/10.3390/v10090461
6. Taubenberger JK. Influenza’s Newest Trick. mBio 2019;10:e02854-19. https://doi.org/10.1128/mBio.02854-19
7. Plaza PI, Gamarra-Toledo V, Euguí JR, Lambertucci SA. Recent Changes in Patterns of Mammal Infection with Highly Pathogenic Avian Influenza A(H5N1) Virus Worldwide. Emerg Infect Dis 2024;30. https://doi.org/10.3201/eid3003.231098
8. Li Y-T, Linster M, Mendenhall IH, Su YCF, Smith GJD. Avian influenza viruses in humans: lessons from past outbreaks. British Medical Bulletin 2019;132:81–95. https://doi.org/10.1093/bmb/ldz036
9. World Health Organization (WHO)/GIP, data in HQ as of 26 February 2024. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2024, 26 February 2024. https://cdn.who.int/media/docs/default-source/influenza/h5n1-human-case-cumulative-table/2024_feb_tableh5n1.pdf?sfvrsn=bccd8c23_1&download=true (access: 2024.06.15)
10. Xie R, Edwards KM, Wille M, Wei X, Wong S-S, Zanin M, et al. The episodic resurgence of highly pathogenic avian influenza H5 virus. Nature 2023;622:810–7. https://doi.org/10.1038/s41586-023-06631-2
11. Venkatesan P. Avian influenza spillover into mammals. The Lancet Microbe 2023;4:e492. https://doi.org/10.1016/S2666-5247(23)00173-8
12. Animal and Plant Health Inspection Service, United States Department of Agriculture. Highly Pathogenic Avian Influenza (HPAI) Detections in Livestock. Available at https://www.aphis.usda.gov/livestock-poultrydisease/avian/avian-influenza/hpai-detections/livestock (access: 2024.06.15)
13. World Health Organization (WHO), Global Influenza Programme, Risk assessments, Ad hoc risk assessments, Joint FAO/WHO/WOAH preliminary assessment of recent influenza A(H5N1) viruses (23April2024). https://cdn.who.int/media/docs/default-source/global-influenza-programme/2024_04_23_fao-woah-who_h5n1_assessment.pdf?sfvrsn=3ca3dba6_2&download=true (access: 2024.06.15)
14. Assessment of risk associated with recent influenza A(H5N1) clade 2.3.4.4b viruses. WHO, Ad hoc risk assessments, 21 December 2022 https://cdn.who.int/media/docs/default-source/influenza/avian-and-other-zoonotic-influenza/h5-risk-assessment-dec-2022.pdf (access: 2024.06.15)
15. Global Initiative on Sharing All Influenza Data (GISAID), Influenza, Phylodynamics of Influenza virus H5Nx across the GlobeP https://gisaid.org/phylogeny-influenza/influenza-h5nx (access: 2024.06.15)
16. World Health Organization (WHO), Disease Outbreak News (DONs) 26 February 2021. https://www.who.int/emergencies/disease-outbreak-news/item/2021-DON313 (access: 2024.06.15)
17. World Health Organization (WHO), Disease Outbreak News (DONs) 07Jun2024. https://cdn.who.int/media/docs/default-source/2021-dha-docs/influenza-at-the-human-animal-interface-summary-and-assessment--from-4-may-to-7-june-2024.pdf?sfvrsn=48c2de05_3&download=true (access:2024.06.28)
18. World Health Organization (WHO), Teams, Global Influenza Programme https://www.who.int/teams/global-influenza-programme (access: 2024.06.15)
19. World Health Organization (WHO), Initiatives, Global Influenza Surveillance and Response System (GISRS) https://www.who.int/initiatives/global-influenza-surveillance-and-response-system (access: 2024.06.15)
20. World Health Organization (WHO), Initiatives, Global Influenza Surveillance and Response System (GISRS), WHO H5 Reference Laboratories https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/h5-reference-laboratories (access: 2024.06.28)
21. World Health Organization (WHO), Institutional Repository for Information Sharing (IRIS), Publications. Genetic and antigenic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic. Weekly Epidemiological Record, 99 (13): 147 - 161. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2024-2025/202402_zoonotic_vaccinvirusupdate.pdf?sfvrsn=70150120_4 (access: 2024.06.15)
22. World Health Organization (WHO), Teams, Global Influenza Programme /vaccines/who-recommendations/Zoonotic influenza viruses and candidate vaccine-viruses https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses (access: 2024.06.15)
23. Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, et al. Antiviral Approaches against Influenza Virus. Clin Microbiol Rev 2023;36:e00040-22. https://doi.org/10.1128/cmr.00040-22
24. Hussain M, Galvin H, Haw TY, Nutsford A, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infection and Drug Resistance. 2017 Apr 1;Volume 10:121–34. https://doi.org/10.2147/idr.s105473
25. Rejestr Produktów Leczniczych/Znajdź produkt leczniczy/Relenza https://rejestry.ezdrowie.gov.pl/api/rpl/medicinal-products/17806/characteristic (access: 2024.06.15)
26. European Commission/Public Health/Union Register of medicinal products/Product information/Dectova https://ec.europa.eu/health/documents/community-register/2020/20200723148657/anx_148657_pl.pdf (access: 2024.06.15)
27. Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, Kimberlin DW, et al. Intravenous Zanamivir in Hospitalized Patients With Influenza. Pediatrics 2017;140:e20162727. https://doi.org/10.1542/peds.2016-2727
28. Earhart KC, Elsayed NM, Saad MD, Gubareva LV, Nayel A, Deyde VM, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. Journal of Infection and Public Health 2009;2:74–80. https://doi.org/10.1016/j.jiph.2009.04.004
29. Kode SS, Pawar SD, Cherian SS, Tare DS, Bhoye D, Keng SS, et al. Selection of avian influenza A (H9N2) virus with reduced susceptibility to neuraminidase inhibitors oseltamivir and zanamivir. Virus Research 2019;265:122–6. https://doi.org/10.1016/j.virusres.2019.03.019
30. Hayden FG, Sugaya N, Hirotsu N, Lee N, De Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018;379:913–23. https://doi.org/10.1056/NEJMoa1716197
31. Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Research 2018;160:109–17. https://doi.org/10.1016/j.antiviral.2018.10.008
32. Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, et al. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1. Emerg Infect Dis 2019;25:1969–72. https://doi.org/10.3201/eid2510.190607
33. World Health Organization (WHO), Institutional Repository for Information Sharing (IRIS), Publications. Guidelines for the clinical management of severe illness from influenza virus infections https://iris.who.int/bitstream/handle/10665/352453/9789240040816-eng.pdf (access: 2024.06.15)
34. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006;442:448–52. https://doi.org/10.1038/nature04795
35. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The Effectiveness of Vaccination against Influenza in Healthy, Working Adults. N Engl J Med 1995;333:889–93. https://doi.org/10.1056/NEJM199510053331401
36. European Medicines Agency (EMA). Human regulatory: overview, Public health threats, Pandemic influenza, Vaccines for pandemic influenza. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/pandemic-influenza/vaccines-pandemic-influenza (access: 2024.06.15)
37. European Medicines Agency (EMA). Medicines. Aflunov https://www.ema.europa.eu/en/medicines/human/EPAR/aflunov-0 (acces: 2024.10.22)
38. European Commission/Public Health - Union Register of medicinal products/Product information/Aflunov. https://ec.europa.eu/health/documents/community-register/2024/20241021164116/anx_164116_pl.pdf (access: 2024.10.22)
39. European Medicines Agency (EMA). Medicines, Zoonotic Influenza Vaccine Seqirus https://www.ema.europa.eu/en/medicines/human/EPAR/zoonotic-influenza-vaccine-seqirus (access: 2024.06.15)
40. Shin D-L, Siebert U, Lakemeyer J, Grilo M, Pawliczka I, Wu N-H, et al. Highly Pathogenic Avian Influenza A(H5N8) Virus in Gray Seals, Baltic Sea. Emerg Infect Dis 2019;25:2295–8. https://doi.org/10.3201/eid2512.181472
41. Shi W, Gao GF. Emerging H5N8 avian influenza viruses. Science 2021;372:784–6. https://doi.org/10.1126/science.abg6302
42. European Commission/Public Health/Union Register of medicinal products/Product information/ Zoonotic Influenza Vaccine Seqirus https://ec.europa.eu/health/documents/community-register/2024/20240613162912/anx_162912_pl.pdf (access: 2024.06.15)
43. European Medicines Agency (EMA). Medicines, Celldemic https://www.ema.europa.eu/en/medicines/human/EPAR/celldemic (access: 2024.06.15)
44. European Commission/Public Health/Union Register of medicinal products/Product information, Celldemic https://ec.europa.eu/health/documents/community-register/2024/20240419162223/anx_162223_pl.pdf (access: 2024.06.15)
45. Holmes EC, Hurt AC, Dobbie Z, Clinch B, Oxford JS, Piedra PA. Understanding the Impact of Resistance to Influenza Antivirals. Clin Microbiol Rev 2021;34:e00224-20. https://doi.org/10.1128/CMR.00224-20
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jacek Fordymacki, Ryszard Łagowski, Julia Kosęda, Barbara Fetner
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 25
Number of citations: 0